XS5A On Other Exchanges
Symbol
Exchange
OTC US
Stuttgart
text size: T | T
Back to Snapshot
Company Description

Contact Info

99 Wood Avenue South

Suite 302

Iselin, NJ 08830

United States

Phone: 732-201-4189

Fax:

Echo Therapeutics, Inc. develops non-invasive, wireless continuous glucose monitoring (CGM) system with potential use in the diabetes outpatient market. The company has also developed its needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose, enhanced delivery of topical pharmaceuticals and other applications. Products CGM The company’s major product is a non-invasive (needle-free), wireless, CGM system designed to provide real-time glucose data continuously. The CGM System includes a skin preparation device, transdermal glucose sensor, battery and wireless transmitter. The transdermal skin preparation component of the system has been developed to be a device to enhance access to the interstitial fluids and enhance the flow of molecules across the protective membrane of the stratum corneum. The skin preparation device incorporates the company’s patented micro-abrasion technology into a hand-held device used to prepare a small area of the skin. The non-invasive sensor is applied to this prepared area to measure the interstitial glucose levels. The key feature of the company’s skin preparation device is its patented feedback mechanism. The device’s proprietary, patented feedback control mechanism consists of software, a microprocessor controlled circuit and measuring electrodes. Drug Delivery The company’s skin preparation device might also have application in the transdermal drug delivery market in addition to markets for other treatments. The localized removal of the stratum corneum created by the device might potentially provide a skin permeation process for the delivery of various topical pharmaceuticals and to facilitate other applications. Partnerships Ferndale Pharma Group, Inc. (Ferndale) The company has a licensing agreement with Ferndale, a group of companies that specialize in the development, manufacture, distribution and marketing of various dermatologic products. Under the terms of the agreement, the company granted Ferndale the right to develop, market, sell and distribute the company’s skin preparation device for skin preparation prior to the application of topical anesthetics or analgesics prior to a range of needle-based medical procedures. In addition to the original territory of North America and the United Kingdom, the license agreement was amended in 2012 to cover South America, Australia, New Zealand, Switzerland and portion of the European Community. This partnership allows the company’s skin permeation technology platform to be combined with Ferndale’s leadership in the topical anesthetic market. Handok, Inc. The company has a license agreement with Handok Inc., a pharmaceutical/healthcare company in Korea with a core business focus in diabetes, cardiovascular, oncology, human vaccines, medical devices, diagnostics and consumer health. Under the terms of the agreement, the company granted Handok, Inc. the right to develop, market, sell and distribute the company’s CGM to medical facilities and individuals in South Korea. Medical Technologies Innovation Asia, Ltd. (MTIA) The company has a license, development and commercialization agreement (the MTIA License) with MTIA. Pursuant to the MTIA License, the company granted MTIA rights to exclusively research, develop, manufacture, and use the company’s CGM in connection with the development activities needed for regulatory approval in the People’s Republic of China, Hong Kong, Macau, and Taiwan; and exclusively make, have made, use, sell, have sold, offer for sale and import the company’s CGM in the Territory once regulatory approval has been received. Intellectual Property As of March 4, 2016, the company had 9 issued U.S. patents and 38 issued foreign patents, and had 23 patent applications pending worldwide. Research and Development For the year ended December 31, 2015, the company’s research and development expenses included $2,788,938. History Echo Therapeutics, Inc. was founded in 1989.

 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

XS5A Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for XS5A.
View Industry Companies
 

Industry Analysis

XS5A

Industry Average

Valuation XS5A Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ECHO THERAPEUTICS INC, please visit www.echotx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.